Your basket is currently empty!
Mastering Pharmacokinetics and Immunogenicity of bispecific antibodies
Dr. Bernd Schlereth of Covagen presents their bispecific Fynomer/FynomAb technology for treatment of inflammatory disease. He describes their PK and Immunogenicity testing strategy including multiple assays to asses early and late ADA response.